在心脏再同步治疗中,单个左心室节奏基于速度适应性心房延迟算法的长期益处
Xuejing Yan1, Xuejuan Ma2, Lulu Zhao1
1Clinical Center of Heart Disease, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Frontiers in cardiovascular medicine
|November 27, 2025
概括
在CRT患者中,速度适应性心房延迟 (RAAVD) 单个左心室节奏 (LUVP) 显著改善心脏功能,减少再住院,并延长电池寿命,而不是双心室节奏 (BVP).
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 医疗器械 医疗器械
背景情况:
- 目前的心脏再同步治疗 (CRT) 准则缺乏长期数据,比较单左心室节奏 (LUVP) 与双心室节奏 (BVP).
- 这项研究解决了这一差距,评估了新型RAAVD算法引导的LUVP与传统BVP的临床优势.
研究的目的:
- 为了比较RAAVD LUVP与BVP的长期临床结果和设备性能,在CRT和完全左捆分支阻塞 (CLBBB) 的患者中.
- 评估RAAVD LUVP对与疾病相关的再住院治疗,设备并发症,电池寿命,心脏结构,功能和同步的影响.
主要方法:
- 一项回顾性队列研究包括67名CRT和CLBBB患者,分为RAAVD LUVP (n=42) 和BVP (n=25) 组.
- 随访时间中位数为43.59个月,主要终点包括再住院,设备并发症和电池寿命.
- 评估心脏结构,功能 (LVEF,6分钟的步行距离) 和同步性 (节奏QRS持续时间,Ts-SD12).
主要成果:
- 在RAAVD LUVP中,再住院率显著降低 (23.8%与48.0%,P=0.041) 和零设备并发症相比12%在BVP中 (P=0.048).
- 通过RAAVD LUVP (7.95±0.78对比4.66±0.66年,P<0.001) 延长了电池寿命.
- 在LVEF (45.7±13.3%对38.9±10.6%,P=0.034),6分钟步行距离 (P=0.034),减少LAD (P=0.018) 和LVEDd (P=0.01) 和更好的同步 (节奏QRS持续时间P=0.001,Ts-SD12 P=0.034) 中观察到显著改善.
结论:
- RAAVD LUVP比传统的BVP提供了持续的临床益处,使CRT与生理状态更紧密地结合在一起.
- RAAVD LUVP与内在导电的动态集成增强了心脏功能和同步.
- 左捆支部区域步调 (LBBAP),LUVP的一个子组,表现出优异的腹腔间同步,突出了步调位置的重要性.
相关概念视频
Cardiomyopathy V: Interprofessional Care
314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Cardiomyopathy II: Dilated Cardiomyopathy
447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447


